» Authors » Milota Kaluzova

Milota Kaluzova

Explore the profile of Milota Kaluzova including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 2252
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Nayyar A, Li M, Sotelo V, Su G, Hwang I, Kaluzova M, et al.
Alzheimers Dement . 2025 Feb; 21(2):e14585. PMID: 39988568
Introduction: Factors influencing plasma Alzheimer's disease (AD) biomarkers remain incompletely understood. Here we evaluated Fujirebio plasma p-Tau in two diverse cohorts among whom 91% underwent cerebrospinal fluid (CSF) analysis. Methods:...
2.
Hu W, Kaluzova M, Dawson A, Sotelo V, Papas J, Lemenze A, et al.
Cell Rep Med . 2024 May; 5(5):101561. PMID: 38744274
Natural history and mechanisms for persistent cognitive symptoms ("brain fog") following acute and often mild COVID-19 are unknown. In a large prospective cohort of people who underwent testing a median...
3.
Chen Z, Giotti B, Kaluzova M, Vallcorba M, Rawat K, Price G, et al.
J Clin Invest . 2023 Sep; 133(22). PMID: 37733448
Monocytes and monocyte-derived macrophages (MDMs) from blood circulation infiltrate glioblastoma (GBM) and promote growth. Here, we show that PDGFB-driven GBM cells induce the expression of the potent proinflammatory cytokine IL-1β...
4.
Hu W, Nayyar A, Kaluzova M
Neurotherapeutics . 2023 Jun; 20(4):955-974. PMID: 37378862
Clinical prediction of underlying pathologic substrates in people with Alzheimer's disease (AD) dementia or related dementia syndromes (ADRD) has limited accuracy. Etiologic biomarkers - including cerebrospinal fluid (CSF) levels of...
5.
Pomeranz Krummel D, Nasti T, Kaluzova M, Kallay L, Bhattacharya D, Melms J, et al.
Int J Radiat Oncol Biol Phys . 2020 Dec; 109(4):1040-1053. PMID: 33289666
Purpose: Most patients with metastatic melanoma show variable responses to radiation therapy and do not benefit from immune checkpoint inhibitors. Improved strategies for combination therapy that leverage potential benefits from...
6.
Lee S, Rehman F, Tyler K, Yu B, Zhang Z, Osuka S, et al.
Clin Cancer Res . 2020 Jan; 26(11):2711-2724. PMID: 31969339
Purpose: Exploitation of altered glycosylation in cancer is a major goal for the design of new cancer therapy. Here, we designed a novel secreted chimeric signal peptide-Galectin-3 conjugate (sGal-3) and...
7.
Freeman A, Platt S, Holmes S, Kent M, Robinson K, Howerth E, et al.
J Neurooncol . 2018 Jan; 137(3):653-663. PMID: 29350351
Cetuximab conjugated iron-oxide nanoparticles (cetuximab-IONPs) have shown both in-vitro and in-vivo anti-tumor efficacy against gliomas. The purpose of this pilot study was to evaluate the safety and potential efficacy of...
8.
Ross J, Cooper L, Kong J, Gutman D, Williams M, Tucker-Burden C, et al.
Sci Rep . 2017 Nov; 7(1):15593. PMID: 29142297
Glioblastoma (GBM) contains diverse microenvironments with uneven distributions of oncogenic alterations and signaling networks. The diffusely infiltrative properties of GBM result in residual tumor at neurosurgical resection margins, representing the...
9.
Kairdolf B, Bouras A, Kaluzova M, Sharma A, Wang M, Hadjipanayis C, et al.
Anal Chem . 2015 Nov; 88(1):858-67. PMID: 26587976
Intraoperative cancer imaging and fluorescence-guided surgery have attracted considerable interest because fluorescence signals can provide real-time guidance to assist a surgeon in differentiating cancerous and normal tissues. Recent advances have...
10.
Bouras A, Kaluzova M, Hadjipanayis C
J Neurooncol . 2015 May; 124(1):13-22. PMID: 25981803
The epidermal growth factor receptor deletion variant EGFRvIII is known to be expressed in a subset of patients with glioblastoma (GBM) tumors that enhances tumorigenicity and also accounts for radiation...